• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes

by MM360 Staff | May 30, 2025 | Uncategorized

Source: CureToday articles Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq. Read More

The Healing Power of Teddy Bears for Adults With Cancer

by MM360 Staff | May 30, 2025 | Uncategorized

Source: CureToday articles There are many instances where teddy bears can be the key to opening hearts and minds during cancer care. Read More

First Patient Treated in Second Cohort of STARLIGHT-1 B-Cell NHL Trial

by MM360 Staff | May 30, 2025 | Uncategorized

Source: CureToday articles The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas. Read More

Antidepressants May Boost Cancer Antitumor Immunity

by MM360 Staff | May 30, 2025 | Uncategorized

Source: CureToday articles Blocking serotonin transporters with antidepressants boosted CD8 T cell function and enhanced immunotherapy response in mouse and human tumor models. Read More

Braftovi and Erbitux Plus Chemo Improves Outcomes for BRAF V600E+ mCRC

by MM360 Staff | May 30, 2025 | Uncategorized

Source: CureToday articles Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting. Read More

Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
  • Streamlining GLP-1 Prior Authorizations: Innovations in Electronic Prior Authorization Technology
  • Patritumab Deruxtecan Does Not Improve Survival Outcomes vs Chemo in EGFR+ NSCLC
  • COCOON Regimen Eases Dermatologic Side Effects After Treatment in EGFR+ NSCLC
  • Kisqali Benefit Lasts Across Age in Breast Cancer Subset
  • New Programs Aim to Improve Implementation of Cardiovascular Interventions
  • Monitoring Patients for Adverse Events and Optimizing Access to Therapies
  • Additional Considerations for LDL-C–Lowering Therapies
  • Zejula Combo Delays Progression in HRR+ Castration-Sensitive Prostate Cancer
  • CDC Clarifies That Kids May Receive COVID-19 Vaccine Through Shared Clinical Decision-Making
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT